BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 22220212)

  • 1. Epigenetic changes of CXCR4 and its ligand CXCL12 as prognostic factors for sporadic breast cancer.
    Ramos EA; Grochoski M; Braun-Prado K; Seniski GG; Cavalli IJ; Ribeiro EM; Camargo AA; Costa FF; Klassen G
    PLoS One; 2011; 6(12):e29461. PubMed ID: 22220212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous CXCL12 and ESR1 CpG island hypermethylation correlates with poor prognosis in sporadic breast cancer.
    Ramos EA; Camargo AA; Braun K; Slowik R; Cavalli IJ; Ribeiro EM; Pedrosa Fde O; de Souza EM; Costa FF; Klassen G
    BMC Cancer; 2010 Jan; 10():23. PubMed ID: 20109227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Down-regulation of CXCL12 mRNA expression by promoter hypermethylation and its association with metastatic progression in human breast carcinomas.
    Zhou W; Jiang Z; Liu N; Xu F; Wen P; Liu Y; Zhong W; Song X; Chang X; Zhang X; Wei G; Yu J
    J Cancer Res Clin Oncol; 2009 Jan; 135(1):91-102. PubMed ID: 18670789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of CXCL12, CXCR4, and CXCR7 in patients with breast cancer.
    Wu W; Qian L; Chen X; Ding B
    Int J Clin Exp Pathol; 2015; 8(10):13217-24. PubMed ID: 26722521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The chemokine receptor CXCR4 is regulated by DNA methylation in pancreatic cancer.
    Sato N; Matsubayashi H; Fukushima N; Goggins M
    Cancer Biol Ther; 2005 Jan; 4(1):70-6. PubMed ID: 15662133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upregulation of CXC chemokine receptor 4-CXC chemokine ligand 12 axis ininvasive breast carcinoma: A potent biomarker predicting lymph node metastasis.
    Dayer R; Babashah S; Jamshidi S; Sadeghizadeh M
    J Cancer Res Ther; 2018; 14(2):345-350. PubMed ID: 29516917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CXCL12-CXCR4 axis promotes the natural selection of breast cancer cell metastasis.
    Sun Y; Mao X; Fan C; Liu C; Guo A; Guan S; Jin Q; Li B; Yao F; Jin F
    Tumour Biol; 2014 Aug; 35(8):7765-73. PubMed ID: 24810923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic silencing of CXCL12 increases the metastatic potential of mammary carcinoma cells.
    Wendt MK; Cooper AN; Dwinell MB
    Oncogene; 2008 Feb; 27(10):1461-71. PubMed ID: 17724466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ITF2 is a target of CXCR4 in MDA-MB-231 breast cancer cells and is associated with reduced survival in estrogen receptor-negative breast cancer.
    Appaiah H; Bhat-Nakshatri P; Mehta R; Thorat M; Badve S; Nakshatri H
    Cancer Biol Ther; 2010 Sep; 10(6):600-14. PubMed ID: 20603605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytoplasmic CXCR4 expression in breast cancer: induction by nitric oxide and correlation with lymph node metastasis and poor prognosis.
    Yasuoka H; Tsujimoto M; Yoshidome K; Nakahara M; Kodama R; Sanke T; Nakamura Y
    BMC Cancer; 2008 Nov; 8():340. PubMed ID: 19025611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Down-regulation of CXCL12 by DNA hypermethylation and its involvement in gastric cancer metastatic progression.
    Zhi Y; Chen J; Zhang S; Chang X; Ma J; Dai D
    Dig Dis Sci; 2012 Mar; 57(3):650-9. PubMed ID: 21960286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrant NDRG1 methylation associated with its decreased expression and clinicopathological significance in breast cancer.
    Han LL; Hou L; Zhou MJ; Ma ZL; Lin DL; Wu L; Ge YL
    J Biomed Sci; 2013 Jul; 20(1):52. PubMed ID: 23899187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promoter hypermethylation-mediated down-regulation of CXCL12 in human astrocytoma.
    Zhou W; Jiang Z; Song X; Liu Y; Wen P; Guo Y; Xu F; Kong L; Zhang P; Han A; Yu J
    J Neurosci Res; 2008 Oct; 86(13):3002-10. PubMed ID: 18512766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast cancer metastasis: demonstration that FOXP3 regulates CXCR4 expression and the response to CXCL12.
    Douglass S; Meeson AP; Overbeck-Zubrzycka D; Brain JG; Bennett MR; Lamb CA; Lennard TW; Browell D; Ali S; Kirby JA
    J Pathol; 2014 Sep; 234(1):74-85. PubMed ID: 24870556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stromal cell derived factor-1 and CXCR4 expression in colorectal cancer promote liver metastasis.
    Amara S; Chaar I; Khiari M; Ounissi D; Weslati M; Boughriba R; Hmida AB; Bouraoui S
    Cancer Biomark; 2015; 15(6):869-79. PubMed ID: 26406413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequent CpG methylation of ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) in sporadic and hereditary Tunisian breast cancer patients: clinical significance.
    Trifa F; Karray-Chouayekh S; Jmaa ZB; Jmal E; Khabir A; Sellami-Boudawara T; Frikha M; Daoud J; Mokdad-Gargouri R
    Med Oncol; 2013 Mar; 30(1):418. PubMed ID: 23315218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic manipulation of stromal cell-derived factor-1 attests the pivotal role of the autocrine SDF-1-CXCR4 pathway in the aggressiveness of breast cancer cells.
    Kang H; Mansel RE; Jiang WG
    Int J Oncol; 2005 May; 26(5):1429-34. PubMed ID: 15809737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tamoxifen epigenetically modulates CXCL12 expression in MCF-7 breast cancer cells.
    Pietkiewicz PP; Lutkowska A; Lianeri M; Jagodzinski PP
    Biomed Pharmacother; 2010 Jan; 64(1):54-7. PubMed ID: 19748759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential estrogen-regulation of CXCL12 chemokine receptors, CXCR4 and CXCR7, contributes to the growth effect of estrogens in breast cancer cells.
    Boudot A; Kerdivel G; Habauzit D; Eeckhoute J; Le Dily F; Flouriot G; Samson M; Pakdel F
    PLoS One; 2011; 6(6):e20898. PubMed ID: 21695171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CXCL12 promoter methylation and PD-L1 expression as prognostic biomarkers in prostate cancer patients.
    Goltz D; Holmes EE; Gevensleben H; Sailer V; Dietrich J; Jung M; Röhler M; Meller S; Ellinger J; Kristiansen G; Dietrich D
    Oncotarget; 2016 Aug; 7(33):53309-53320. PubMed ID: 27462860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.